Journal Watch · Journal of Medicinal Chemistry · 2026

Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.

These findings validate this dual-targeting PROTAC/IMiD strategy as an effective approach to overcoming the limitations of selective BRD9 degraders, underscoring its therapeutic potential in hematologic malignancies.

Duan H, Chen R, Zhang J et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.6c00801PMID: 42720456Study type: preclinical (animal / model) study

TL;DR

These findings validate this dual-targeting PROTAC/IMiD strategy as an effective approach to overcoming the limitations of selective BRD9 degraders, underscoring its therapeutic potential in hematologic malignancies.

Key findings

  • In the OCI-ly10 xenograft model, B8 achieved near-complete tumor regression (TGI > 99%), significantly outperforming the selective BRD9 PROTAC E5 (TGI = 31%), without detectable toxicity or MYC upregulation.
  • These findings validate this dual-targeting PROTAC/IMiD strategy as an effective approach to overcoming the limitations of selective BRD9 degraders, underscoring its therapeutic potential in hematologic malignancies.

Numbers at a glance (from the abstract)

99%31%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Utilizing ternary complex modeling and structure-activity relationship (SAR) analysis, aromatic linkers and modified E3 ligands facilitated efficient degradation. The lead candidate, B8, induces potent and selective degradation of both BRD9 (DC50 = 57 pM) and IKZF1 (DC50 = 62 pM). B8 showed broad antiproliferative activity across hematologic malignancy cells, particularly lymphomas.

Full abstract (original)

Background: Bromodomain-containing protein 9 (BRD9) has emerged as an epigenetic target in hematologic malignancies. However, previous studies on BRD9 PROTACs reported MYC upregulation following chronic administration. Here, we describe bifunctional BRD9 PROTAC/immunomodulatory drug (IMiD) degraders engineered to simultaneously eliminate BRD9 and IKZF1.

What they did: Utilizing ternary complex modeling and structure-activity relationship (SAR) analysis, aromatic linkers and modified E3 ligands facilitated efficient degradation. The lead candidate, B8, induces potent and selective degradation of both BRD9 (DC50 = 57 pM) and IKZF1 (DC50 = 62 pM). B8 showed broad antiproliferative activity across hematologic malignancy cells, particularly lymphomas.

Results & conclusions: In the OCI-ly10 xenograft model, B8 achieved near-complete tumor regression (TGI > 99%), significantly outperforming the selective BRD9 PROTAC E5 (TGI = 31%), without detectable toxicity or MYC upregulation. These findings validate this dual-targeting PROTAC/IMiD strategy as an effective approach to overcoming the limitations of selective BRD9 degraders, underscoring its therapeutic potential in hematologic malignancies.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00801 · PubMed 42720456.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

These findings validate this dual-targeting PROTAC/IMiD strategy as an effective approach to overcoming the limitations of selective BRD9 degraders, underscoring its therapeutic potential in hematologic malignancies.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Utilizing ternary complex modeling and structure-activity relationship (SAR) analysis, aromatic linkers and modified E3 ligands facilitated efficient degradation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00801. PubMed ID: 42720456. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Duan H, Chen R, Zhang J et al.. Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c00801.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-brd9-protac-imid-bifunctional-molecules-as-potent-therapeut-c00801/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides